Remdesivir is expected to be in high demand as one of the only treatments so far shown to alter the course of COVID-19
30 Jun 2020 11:23 AM
Gilead Sciences signed similar non-exclusive licensing agreements with Cipla, Hetero Labs, Jubilant Lifesciences, Mylan and Zydus Cadila
14 Jun 2020 9:59 AM
The Food and Drug Administration has issued a warning about its use
19 May 2020 10:15 AM